Illumina, Inc. (ILMN) EVP Omead Ostadan Sells 3,540 Shares

Illumina, Inc. (NASDAQ:ILMN) EVP Omead Ostadan sold 3,540 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $226.91, for a total value of $803,261.40. Following the completion of the transaction, the executive vice president now directly owns 26,827 shares in the company, valued at approximately $6,087,314.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of Illumina, Inc. (ILMN) traded down $2.39 on Wednesday, hitting $211.06. 1,050,000 shares of the stock traded hands, compared to its average volume of 958,333. Illumina, Inc. has a twelve month low of $119.37 and a twelve month high of $230.72. The firm has a market capitalization of $31,163.70, a P/E ratio of 62.41, a price-to-earnings-growth ratio of 3.53 and a beta of 0.79. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.12. The business had revenue of $714.00 million during the quarter, compared to the consensus estimate of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.97 earnings per share. sell-side analysts forecast that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.

Several research firms recently commented on ILMN. BidaskClub lowered Illumina from a “buy” rating to a “hold” rating in a report on Wednesday. Barclays reissued an “equal weight” rating and issued a $150.00 target price on shares of Illumina in a report on Wednesday, August 9th. Vetr raised Illumina from a “hold” rating to a “buy” rating and set a $209.78 target price on the stock in a report on Wednesday, August 9th. Goldman Sachs Group restated a “neutral” rating and issued a $200.00 price objective on shares of Illumina in a research note on Tuesday, September 26th. Finally, Canaccord Genuity restated a “buy” rating and issued a $230.00 price objective (up previously from $215.00) on shares of Illumina in a research note on Thursday, October 12th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the stock. Illumina currently has an average rating of “Buy” and an average target price of $201.98.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dupont Capital Management Corp purchased a new position in Illumina during the third quarter worth about $153,000. Advisory Services Network LLC raised its holdings in Illumina by 13.0% during the second quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after purchasing an additional 89 shares in the last quarter. Penserra Capital Management LLC raised its holdings in Illumina by 13.0% during the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after purchasing an additional 102 shares in the last quarter. Paradigm Asset Management Co. LLC raised its holdings in Illumina by 5.6% during the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after purchasing an additional 50 shares in the last quarter. Finally, West Coast Financial LLC purchased a new position in Illumina during the third quarter worth about $216,000. 91.75% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Illumina, Inc. (ILMN) EVP Omead Ostadan Sells 3,540 Shares” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://ledgergazette.com/2017/12/06/illumina-inc-ilmn-evp-omead-ostadan-sells-3540-shares.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply